Google
BNTX Stock Price & Analysis — Biontech SE (Healthcare >> Biotechnology)
BNTX FAQ
What is BNTX's P/E ratio?
Biontech SE (BNTX) currently trades at a P/E ratio of -818.13.
What is BNTX's ROE?
Biontech SE reports a Return on Equity (ROE) of -6.72%.
What is BNTX's dividend yield?
Biontech SE offers a dividend yield of 0.00%.
What is BNTX's Quality Score?
Our AI rates BNTX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BNTX?
Our AI Timing Score for BNTX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BNTX belong to?
Biontech SE is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
BNTX AI Analysis Summary
Our AI summary for BNTX: Biontech SE (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of -818.13, ROE of -6.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 90.58
Price
-2.27
(-2.44%)
Day Change
|
|
|---|
BNTX, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 68 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 90.58 |
| PBV / Sector |
1.25 / 5.20
GOOD
|
| Earning Per Share | -4.85 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
12.34 / 1.22
|
| Average 1M Daily Value |
69.48 M
|
| Average 1W Daily Value |
76.22 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
52% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:34 |
| Symbol | BNTX |
| Name | BIONTECH SE |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 252.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23,480.30 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: An der Goldgrube 12, Mainz, Germany, 55131
Phone: 49 6131 9084
Website: https://www.biontech.de
Employees: 7,807
Sector: Healthcare >> Biotechnology
Description: BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap